Biotech deals surge to record as fear of missing out grips Big Pharma

The pharmaceutical industry is experiencing a surge in biotech deals, driven by the looming threat of patents expiring on top-selling drugs. Companies are aggressively seeking new blockbuster medicines to maintain their revenue streams. This wave of mergers and acquisitions highlights a strategic shift as Big Pharma aims to stay ahead in the competitive landscape, fearing the loss of lucrative market positions. The trend underscores the industry's focus on innovation and the importance of staying relevant in the face of evolving market dynamics.